Acute	B:C0877055
generalized	I:C0877055
exanthematous	I:C0877055
pustulosis	I:C0877055
secondary	O
to	O
levetiracetam	O
and	O
valproic	O
acid	I:C0078004
use	O
.	O

Acute	O
generalized	I:C0877055
exanthematous	I:C0877055
pustulosis	I:C0877055
secondary	O
to	O
levetiracetam	B:C0377265
and	O
valproic	O
acid	I:C0078004
use	O
.	O

Acute	O
generalized	I:C0877055
exanthematous	I:C0877055
pustulosis	I:C0877055
secondary	O
to	O
levetiracetam	O
and	O
valproic	B:C0078004
acid	I:C0078004
use	O
.	O

Acute	B:C0877055
generalized	I:C0877055
exanthematous	I:C0877055
pustulosis	I:C0877055
(	O
AGEP	I:C0877055
)	I:C0877055
is	O
a	O
rare	O
cutaneous	O
eruption	I:C0015230
characterized	O
by	O
the	O
appearance	O
of	O
diffuse	O
,	O
sterile	O
pustules	I:C4015236
on	O
an	O
erythematous	O
and	O
edematous	O
base	I:C0013604
.	O

Acute	O
generalized	I:C0877055
exanthematous	I:C0877055
pustulosis	I:C0877055
(	B:C0877055
AGEP	I:C0877055
)	I:C0877055
is	O
a	O
rare	O
cutaneous	O
eruption	I:C0015230
characterized	O
by	O
the	O
appearance	O
of	O
diffuse	O
,	O
sterile	O
pustules	I:C4015236
on	O
an	O
erythematous	O
and	O
edematous	O
base	I:C0013604
.	O

Acute	O
generalized	I:C0877055
exanthematous	I:C0877055
pustulosis	I:C0877055
(	O
AGEP	I:C0877055
)	I:C0877055
is	O
a	O
rare	O
cutaneous	B:C0015230
eruption	I:C0015230
characterized	O
by	O
the	O
appearance	O
of	O
diffuse	O
,	O
sterile	O
pustules	I:C4015236
on	O
an	O
erythematous	O
and	O
edematous	O
base	I:C0013604
.	O

Acute	O
generalized	I:C0877055
exanthematous	I:C0877055
pustulosis	I:C0877055
(	O
AGEP	I:C0877055
)	I:C0877055
is	O
a	O
rare	O
cutaneous	O
eruption	I:C0015230
characterized	O
by	O
the	O
appearance	O
of	O
diffuse	B:C0205219
,	O
sterile	O
pustules	I:C4015236
on	O
an	O
erythematous	O
and	O
edematous	O
base	I:C0013604
.	O

Acute	O
generalized	I:C0877055
exanthematous	I:C0877055
pustulosis	I:C0877055
(	O
AGEP	I:C0877055
)	I:C0877055
is	O
a	O
rare	O
cutaneous	O
eruption	I:C0015230
characterized	O
by	O
the	O
appearance	O
of	O
diffuse	O
,	O
sterile	B:C4015236
pustules	I:C4015236
on	O
an	O
erythematous	O
and	O
edematous	O
base	I:C0013604
.	O

Acute	O
generalized	I:C0877055
exanthematous	I:C0877055
pustulosis	I:C0877055
(	O
AGEP	I:C0877055
)	I:C0877055
is	O
a	O
rare	O
cutaneous	O
eruption	I:C0015230
characterized	O
by	O
the	O
appearance	O
of	O
diffuse	O
,	O
sterile	O
pustules	I:C4015236
on	O
an	O
erythematous	B:C0041834
and	O
edematous	O
base	I:C0013604
.	O

Acute	O
generalized	I:C0877055
exanthematous	I:C0877055
pustulosis	I:C0877055
(	O
AGEP	I:C0877055
)	I:C0877055
is	O
a	O
rare	O
cutaneous	O
eruption	I:C0015230
characterized	O
by	O
the	O
appearance	O
of	O
diffuse	O
,	O
sterile	O
pustules	I:C4015236
on	O
an	O
erythematous	O
and	O
edematous	B:C0013604
base	I:C0013604
.	O

Most	O
cases	O
are	O
attributed	O
to	O
drug	B:C0041755
reactions	I:C0041755
,	O
with	O
antibiotics	O
being	O
the	O
most	O
common	O
offending	O
agents	I:C0450442
.	O

Most	O
cases	O
are	O
attributed	O
to	O
drug	O
reactions	I:C0041755
,	O
with	O
antibiotics	B:C0003232
being	O
the	O
most	O
common	O
offending	O
agents	I:C0450442
.	O

Most	O
cases	O
are	O
attributed	O
to	O
drug	O
reactions	I:C0041755
,	O
with	O
antibiotics	O
being	O
the	O
most	O
common	O
offending	B:C0450442
agents	I:C0450442
.	O

Only	O
a	O
handful	O
of	O
case	B:C0085973
reports	I:C0085973
have	O
described	O
Acute	O
generalized	I:C0877055
exanthematous	I:C0877055
pustulosis	I:C0877055
in	O
the	O
setting	O
of	O
antiepileptic	O
use	O
.	O

Only	O
a	O
handful	O
of	O
case	O
reports	I:C0085973
have	O
described	O
Acute	B:C0877055
generalized	I:C0877055
exanthematous	I:C0877055
pustulosis	I:C0877055
in	O
the	O
setting	O
of	O
antiepileptic	O
use	O
.	O

Only	O
a	O
handful	O
of	O
case	O
reports	I:C0085973
have	O
described	O
Acute	O
generalized	I:C0877055
exanthematous	I:C0877055
pustulosis	I:C0877055
in	O
the	O
setting	O
of	O
antiepileptic	B:C0003299
use	O
.	O

Here	O
,	O
we	O
report	B:C0684224
a	O
case	O
of	O
Acute	O
generalized	I:C0877055
exanthematous	I:C0877055
pustulosis	I:C0877055
secondary	O
to	O
dual	O
antiepileptic	O
therapy	O
with	O
levetiracetam	O
and	O
valproic	O
acid	I:C0078004
in	O
a	O
73	O
-	O
year	O
-	O
old	O
female	O
.	O

Here	O
,	O
we	O
report	O
a	O
case	O
of	O
Acute	B:C0877055
generalized	I:C0877055
exanthematous	I:C0877055
pustulosis	I:C0877055
secondary	O
to	O
dual	O
antiepileptic	O
therapy	O
with	O
levetiracetam	O
and	O
valproic	O
acid	I:C0078004
in	O
a	O
73	O
-	O
year	O
-	O
old	O
female	O
.	O

Here	O
,	O
we	O
report	O
a	O
case	O
of	O
Acute	O
generalized	I:C0877055
exanthematous	I:C0877055
pustulosis	I:C0877055
secondary	O
to	O
dual	O
antiepileptic	B:C0003299
therapy	O
with	O
levetiracetam	O
and	O
valproic	O
acid	I:C0078004
in	O
a	O
73	O
-	O
year	O
-	O
old	O
female	O
.	O

Here	O
,	O
we	O
report	O
a	O
case	O
of	O
Acute	O
generalized	I:C0877055
exanthematous	I:C0877055
pustulosis	I:C0877055
secondary	O
to	O
dual	O
antiepileptic	O
therapy	B:C0087111
with	O
levetiracetam	O
and	O
valproic	O
acid	I:C0078004
in	O
a	O
73	O
-	O
year	O
-	O
old	O
female	O
.	O

Here	O
,	O
we	O
report	O
a	O
case	O
of	O
Acute	O
generalized	I:C0877055
exanthematous	I:C0877055
pustulosis	I:C0877055
secondary	O
to	O
dual	O
antiepileptic	O
therapy	O
with	O
levetiracetam	B:C0377265
and	O
valproic	O
acid	I:C0078004
in	O
a	O
73	O
-	O
year	O
-	O
old	O
female	O
.	O

Here	O
,	O
we	O
report	O
a	O
case	O
of	O
Acute	O
generalized	I:C0877055
exanthematous	I:C0877055
pustulosis	I:C0877055
secondary	O
to	O
dual	O
antiepileptic	O
therapy	O
with	O
levetiracetam	O
and	O
valproic	B:C0078004
acid	I:C0078004
in	O
a	O
73	O
-	O
year	O
-	O
old	O
female	O
.	O

Here	O
,	O
we	O
report	O
a	O
case	O
of	O
Acute	O
generalized	I:C0877055
exanthematous	I:C0877055
pustulosis	I:C0877055
secondary	O
to	O
dual	O
antiepileptic	O
therapy	O
with	O
levetiracetam	O
and	O
valproic	O
acid	I:C0078004
in	O
a	O
73	O
-	O
year	O
-	O
old	B:C0001792
female	O
.	O

The	O
patient	O
presented	O
to	O
the	O
emergency	B:C0562508
department	I:C0562508
with	O
the	O
characteristic	O
Acute	O
generalized	I:C0877055
exanthematous	I:C0877055
pustulosis	I:C0877055
rash	O
,	O
fever	O
,	O
and	O
leukocytosis	O
.	O

The	O
patient	O
presented	O
to	O
the	O
emergency	O
department	I:C0562508
with	O
the	O
characteristic	O
Acute	B:C0877055
generalized	I:C0877055
exanthematous	I:C0877055
pustulosis	I:C0877055
rash	O
,	O
fever	O
,	O
and	O
leukocytosis	O
.	O

The	O
patient	O
presented	O
to	O
the	O
emergency	O
department	I:C0562508
with	O
the	O
characteristic	O
Acute	O
generalized	I:C0877055
exanthematous	I:C0877055
pustulosis	I:C0877055
rash	B:C0015230
,	O
fever	O
,	O
and	O
leukocytosis	O
.	O

The	O
patient	O
presented	O
to	O
the	O
emergency	O
department	I:C0562508
with	O
the	O
characteristic	O
Acute	O
generalized	I:C0877055
exanthematous	I:C0877055
pustulosis	I:C0877055
rash	O
,	O
fever	B:C0015967
,	O
and	O
leukocytosis	O
.	O

The	O
patient	O
presented	O
to	O
the	O
emergency	O
department	I:C0562508
with	O
the	O
characteristic	O
Acute	O
generalized	I:C0877055
exanthematous	I:C0877055
pustulosis	I:C0877055
rash	O
,	O
fever	O
,	O
and	O
leukocytosis	B:C0023518
.	O

Upon	O
discontinuation	B:C1444662
of	O
the	O
two	O
medications	O
and	O
conservative	O
management	I:C0459914
,	O
the	O
patient	O
's	O
symptoms	O
quickly	O
abated	O
,	O
and	O
she	O
was	O
discharged	O
from	O
the	O
hospital	O
several	O
days	I:C3845714
later	O
.	O

Upon	O
discontinuation	O
of	O
the	O
two	O
medications	B:C4284232
and	O
conservative	O
management	I:C0459914
,	O
the	O
patient	O
's	O
symptoms	O
quickly	O
abated	O
,	O
and	O
she	O
was	O
discharged	O
from	O
the	O
hospital	O
several	O
days	I:C3845714
later	O
.	O

Upon	O
discontinuation	O
of	O
the	O
two	O
medications	O
and	O
conservative	B:C0459914
management	I:C0459914
,	O
the	O
patient	O
's	O
symptoms	O
quickly	O
abated	O
,	O
and	O
she	O
was	O
discharged	O
from	O
the	O
hospital	O
several	O
days	I:C3845714
later	O
.	O

Upon	O
discontinuation	O
of	O
the	O
two	O
medications	O
and	O
conservative	O
management	I:C0459914
,	O
the	O
patient	O
's	O
symptoms	B:C1457887
quickly	O
abated	O
,	O
and	O
she	O
was	O
discharged	O
from	O
the	O
hospital	O
several	O
days	I:C3845714
later	O
.	O

Upon	O
discontinuation	O
of	O
the	O
two	O
medications	O
and	O
conservative	O
management	I:C0459914
,	O
the	O
patient	O
's	O
symptoms	O
quickly	O
abated	O
,	O
and	O
she	O
was	O
discharged	B:C0030685
from	O
the	O
hospital	O
several	O
days	I:C3845714
later	O
.	O

Upon	O
discontinuation	O
of	O
the	O
two	O
medications	O
and	O
conservative	O
management	I:C0459914
,	O
the	O
patient	O
's	O
symptoms	O
quickly	O
abated	O
,	O
and	O
she	O
was	O
discharged	O
from	O
the	O
hospital	B:C0019994
several	O
days	I:C3845714
later	O
.	O

Upon	O
discontinuation	O
of	O
the	O
two	O
medications	O
and	O
conservative	O
management	I:C0459914
,	O
the	O
patient	O
's	O
symptoms	O
quickly	O
abated	O
,	O
and	O
she	O
was	O
discharged	O
from	O
the	O
hospital	O
several	B:C3845714
days	I:C3845714
later	O
.	O

